8-K: Relay Therapeutics' Zovegalisib Gets FDA Breakthrough Status

Relay Therapeutics announced that its drug candidate, zovegalisib, received Breakthrough Therapy designation from the FDA for advanced breast cancer.

Summary

• Relay Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) for zovegalisib (RLY-2608).
• The designation is for zovegalisib in combination with fulvestrant for adults with PIK3CA mutant hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
• Approximately 40% of patients with HR+/HER2advanced breast cancer harbor PIK3CA mutations, and most experience disease recurrence or progression following treatment with CDK4/6 inhibitors, leaving limited therapeutic options.
• BTD is designed to accelerate the development and review of therapies for serious conditions when early clinical evidence suggests the potential for substantial improvement over available treatments.
• The designation was supported by clinical data from the Phase 1/2 ReDiscover trial, specifically data across all PIK3CA mutations for two doses: 600mg BID fasted (N=52) and 400mg BID fed (N=57), the latter being the dose used in the ongoing Phase 3 trial, ReDiscover-2.
• Zovegalisib is the first known allosteric, pan-mutant, and isoform-selective PI3K inhibitor, designed to overcome limitations of traditional PI3K inhibitors such as toxicity and lack of selectivity.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, as Breakthrough Therapy designation significantly de-risks the regulatory pathway and highlights the strong potential of zovegalisib to address a critical unmet medical need.

Positives

• Zovegalisib (RLY-2608) received Breakthrough Therapy designation from the FDA, indicating its potential for substantial improvement over available treatments for a serious condition.
• The BTD accelerates the development and review process, providing eligibility for Fast Track features, enhanced FDA guidance, and increased engagement with senior FDA leadership, potentially bringing the therapy to patients faster.
• The drug targets a significant unmet medical need in approximately 40% of HR+/HER2advanced breast cancer patients with PIK3CA mutations who have progressed on CDK4/6 inhibitors.
• Zovegalisib's novel mechanism as the first known allosteric, pan-mutant, and isoform-selective PI3K inhibitor suggests a potentially superior therapeutic profile compared to previous PI3K inhibitors.
• The drug also has potential for an estimated 170,000 patients with vascular anomalies driven by a PI3K mutation per year in the United States, expanding its market opportunity.

Negatives

• None.

Risks

• The impact of global economic uncertainty, geopolitical instability, conflicts, or public health epidemics on operations, clinical trial timing, strategy, and profitability.
• Potential delays or pauses in current or planned clinical trials or the development of drug candidates.
• Preliminary or interim results of preclinical or clinical trials may not be predictive of future or final results, and interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures.
• Inability to successfully demonstrate the safety and efficacy of drug candidates.
• Uncertainty regarding the timing and outcome of interactions with regulatory authorities and obtaining related approvals.
• Risks associated with obtaining, maintaining, and protecting intellectual property.

Future Outlook

The company anticipates continuing to collaborate closely with the FDA to advance the zovegalisib program as efficiently as possible. They expect the Breakthrough Therapy designation to accelerate development and review, potentially leading to faster market access for patients with PIK3CA mutant HR+/HER2advanced breast cancer.

Management Comments

• "This Breakthrough Therapy designation underscores the FDAs recognition of the potential of zovegalisib in combination with fulvestrant to meaningfully improve outcomes for these patients, reinforcing the impact of the encouraging clinical evidence we have demonstrated to date."
• "We look forward to continuing to collaborate closely with the FDA as we work to advance this program as efficiently as possible for patients."

Industry Context

StockSavvy.ai notes that the FDA's Breakthrough Therapy designation is a significant regulatory milestone, signaling the agency's belief in zovegalisib's potential to offer substantial improvement over existing treatments for a serious condition. This designation places Relay Therapeutics' candidate in an accelerated development pathway, potentially giving it a competitive edge in the advanced breast cancer market, particularly for patients with PIK3CA mutations who have limited options after CDK4/6 inhibitor failure. This could position Relay Therapeutics favorably against other oncology developers targeting similar patient populations.

Comparison to Industry Standards

• The Breakthrough Therapy designation is a highly selective status, granted to therapies that demonstrate preliminary clinical evidence of substantial improvement over available treatments for serious conditions. This places zovegalisib in an elite category of drug candidates, similar to other therapies that have received BTD and subsequently achieved accelerated approval or faster review times.
• Traditional PI3K inhibitors, such as alpelisib (Novartis' Piqray), have faced challenges with toxicity and limited selectivity for mutant versus wild-type PI3K. Zovegalisib, as the first known allosteric, pan-mutant, and isoform-selective PI3K inhibitor, aims to overcome these limitations, potentially offering a better therapeutic index and improved patient tolerability compared to existing or prior generation PI3K inhibitors.

Stakeholder Impact

• Shareholders: Positive impact due to accelerated development, increased likelihood of approval, and potential for significant market opportunity, which could drive stock value.
• Patients: Highly positive impact as it suggests a potentially life-changing therapy for a serious condition with limited options, with the potential for faster access to treatment.
• Healthcare Providers: Provides a new, potentially more effective and tolerable treatment option for a challenging patient population.
• Regulatory Authorities: Demonstrates the FDA's commitment to accelerating promising therapies for unmet medical needs.

Next Steps

• Continue collaboration with the FDA to advance the zovegalisib program.
• Present initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients at ESMO Targeted Anticancer Therapies Congress on March 16.
• Continue evaluation of zovegalisib in multiple metastatic breast cancer studies and a first-in-human study for PIK3CA mutation-driven vascular anomalies.

Key Dates

Recommendation

The FDA Breakthrough Therapy designation is a major positive catalyst, significantly de-risking the regulatory pathway for zovegalisib and highlighting its strong clinical potential in a high unmet need breast cancer population. This accelerates the drug's development and review, increasing the probability of market approval and future revenue generation. The unique allosteric mechanism also suggests a differentiated profile. This news warrants a strong buy recommendation for investors seeking exposure to innovative oncology therapies with accelerated regulatory timelines.

Keywords

Relay Therapeutics, RLAY, Zovegalisib, RLY-2608, Breakthrough Therapy Designation, FDA, Breast Cancer, PIK3CA mutant, HR+/HER2-, Metastatic Breast Cancer, Oncology, Clinical Trial, ReDiscover trial, PI3K inhibitor, Precision Medicine